SLC27A2 and diabetes mellitus: One potential clinical implication is that, in contrast to diabetes treatment with GLP-1 receptor agonists, which ostensibly mimic the effect of endogenous GLP-1, FATP2 inhibition may represent a more natural stimulus of α cell GLP-1 augmentation.